Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

Name of entity	SIGMA PHARMACEUTICALS LIMITED	
ABN	ABN 15 088 417 403	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Robert HOOPER
Date of last notice	25/03/2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	10/07/2015	
No. of securities held prior to change	33,059,601	
	Ordinary Shares	3,429,742
	Shares allocated pursuant to the employee share plan	18,612
	Shares allocated pursuant to the loan funded long term incentive plan	29,106,649
	Short term incentive plan performance rights	504,598
Class	Ordinary	
Number acquired	7,500	
Number disposed		

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,752.50	
No. of securities held after change	33,067,101	
	Ordinary Shares 3,429,	742
	Shares allocated pursuant to the employee share plan 26,	112
	Shares allocated pursuant to the loan funded long term incentive plan 29,106,0	649
	Short term incentive plan performance rights 504,8	598
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares allocated pursuant to Sigma's Employee Share Plan.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – *Closed period

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

01/01/2011 Appendix 3Y Page 3

⁺ See chapter 19 for defined terms.